# Pertuzumab + Trastuzumab

## Phesgo inj 600/600mg/10mL

##### 臨採

| TAH Drug Code      | [IPHES](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPHES)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, Adjuvant, HER2-positive, early stage, at high risk of recurrence, in combination with chemotherapyView additional information. Breast cancer, Neoadjuvant, HER2-positive, locally advanced, inflammatory, or early stage (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen in combination with chemotherapyView additional information. Metastatic breast cancer, HER2-positive, in combination with docetaxel, in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease                                                                                                                                                                                                                                                                                                 |
| Dosing             | Initial dosage, Pertuzumab 1200mg/Trastuzumab 600mg/Hyaluronidase-zzxf 30000units, 15mL, SC over approximately 8 minutes. Maintenance dosage: Pertuzumab 600mg/Trastuzumab 600mg/Hyaluronidase-zzxf 20000units, 10mL, SC over approximately 5 minutes every 3 weeks for 3 to 6 cycles as part of a treatment regimen.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to pertuzumab, trastuzumab, or hyaluronidase, or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Common Dermatologic: Alopecia (77% ), Injection site disorder (15% ), Radiation injury (19% ), Rash (16% ) Gastrointestinal: Constipation (22% ), Decrease in appetite (17% ), Diarrhea (60% ), Inflammatory disease of mucous membrane (15% ), Nausea (60% ), Stomatitis (25% ), Taste sense altered (17% ), Vomiting (20% ) Hematologic: Anemia, All Grades (36% ), Neutropenia, All Grades (22% ) Musculoskeletal: Arthralgia (24% ) Neurologic: Asthenia (31% ), Headache (17% ), Insomnia (17% ), Sensory neuropathy (16% ) Other: Fatigue (29% ) Serious Cardiovascular: Cardiomyopathy, Heart failure (0.8% ), Left ventricular cardiac dysfunction Hematologic: Febrile neutropenia, Grade 3 or 4 (7% ), Neutropenia, Grade 3 or 4 (14% ) Immunologic: Anaphylaxis, Hypersensitivity reaction (1.2% ) Respiratory: Pulmonary toxicity Other: Infusion reaction (21% ) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| More Info          | [UpToDate](https://www.uptodate.com/contents/pertuzumab-and-trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

## PHESGO inj 1200/600mg/15mL

##### 臨採

| TAH Drug Code      | [IPHES12](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IPHES12)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Early Breast Cancer (EBC) Used in combination with chemotherapy for: ‧ Neoadjuvant therapy in HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (tumor >2 cm or node-positive), as part of a comprehensive treatment plan. ‧ Adjuvant therapy in HER2-positive early breast cancer patients at high risk of recurrence. Metastatic Breast Cancer (MBC) Used with docetaxel in HER2-positive MBC patients who have not received prior anti-HER2 or chemotherapy for metastatic disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | ●Breast cancer, early, neoadjuvant treatment, HER2 positive: Note: Administer 3 to 6 cycles of pertuzumab/trastuzumab/hyaluronidase as part of a neoadjuvant treatment regimen for early breast cancer. Initial loading dose: SUBQ: Pertuzumab 1,200 mg/trastuzumab 600 mg/hyaluronidase 30,000 units initially, followed 3 weeks later by maintenance dosing. Maintenance dosing: SUBQ: Pertuzumab 600 mg/trastuzumab 600 mg/hyaluronidase 20,000 units once every 3 weeks. Following surgery, continue pertuzumab/trastuzumab/hyaluronidase to complete 1 year of treatment (up to 18 cycles) or until disease progression or unacceptable toxicity, whichever occurs first. ●Breast cancer, early, adjuvant treatment, HER2 positive: Note: Administer as part of a complete regimen for early breast cancer, including anthracycline- and/or taxane-based chemotherapy. If part of anthracycline-based therapy, administer pertuzumab/trastuzumab/hyaluronidase following completion of anthracycline therapy. Initiate pertuzumab/trastuzumab/hyaluronidase on day 1 of the first taxane-containing cycle. Initial loading dose: SUBQ: Pertuzumab 1,200 mg/trastuzumab 600 mg/hyaluronidase 30,000 units initially, followed 3 weeks later by maintenance dosing. Maintenance dosing: SUBQ: Pertuzumab 600 mg/trastuzumab 600 mg/hyaluronidase 20,000 units once every 3 weeks for a total of 1 year (up to 18 cycles) or until disease progression or unacceptable toxicity, whichever occurs first. ●Breast cancer, metastatic, HER2 positive: Note: Administer in combination with docetaxel. Initial loading dose: SUBQ: Pertuzumab 1,200 mg/trastuzumab 600 mg/hyaluronidase 30,000 units initially, followed 3 weeks later by maintenance dosing. Maintenance dosing: SUBQ: Pertuzumab 600 mg/trastuzumab 600 mg/hyaluronidase 20,000 units once every 3 weeks; continue pertuzumab/trastuzumab/hyaluronidase until disease progression or unacceptable toxicity, whichever occurs first.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Known hypersensitivity to pertuzumab, trastuzumab, or hyaluronidase, or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | >10%: Dermatologic: Alopecia (77%), skin rash (16%), xeroderma (15%) Endocrine & metabolic: Decreased serum albumin (16%), decreased serum sodium (13%), hot flash (11% to 12%), increased serum potassium (13%), weight loss (11%) Gastrointestinal: Constipation (22%), decreased appetite (17%), diarrhea (17% to 60%; grades 3/4: 7%), dysgeusia (17%), dyspepsia (12% to 14%), nausea (60%; grades 3/4: 2%), stomatitis (15% to 25%; grades 3/4: ?1%), vomiting (20%; grades 3/4: <1%) Hematologic & oncologic: Anemia (36%; grades 3/4: 2%), decreased absolute lymphocyte count (89%; grades 3/4: 37%), decreased platelet count (27%), neutropenia (22%; grades 3/4: 14%) Hepatic: Increased serum alanine aminotransferase (58%), increased serum aspartate aminotransferase (50%) Local: Injection-site reaction (13% to 15%; including pain at injection site [2%]) Nervous system: Asthenia (11% to 31%), dizziness (13%), fatigue (29%), headache (17%), insomnia (17%), peripheral neuropathy (12%; grades 3/4: <1%), peripheral sensory neuropathy (16%), procedural pain (13%) Neuromuscular & skeletal: Arthralgia (19% to 24%), myalgia (25%) Renal: Increased serum creatinine (84%) Respiratory: Cough (15%), epistaxis (12%), upper respiratory tract infection (11%) Miscellaneous: Fever (13%), radiation injury (skin: 19% to 20%) 1% to 10%: Cardiovascular: Heart failure (?1%), peripheral edema (8%), reduced ejection fraction (4%) Dermatologic: Dermatitis (7%), erythema of skin (9%), nail discoloration (9%), nail disease (7%), palmar-plantar erythrodysesthesia (6%), paronychia (7%), pruritus (3% to 10%) Endocrine & metabolic: Decreased serum glucose (9%), hypokalemia (7%), increased serum sodium (7%) Gastrointestinal: Abdominal pain (9%), hemorrhoids (9%), upper abdominal pain (8%) Genitourinary: Urinary tract infection (7%) Hematologic & oncologic: Febrile neutropenia (7%; grades 3/4: 7%), leukopenia (9%; grades 3/4: 2%) Hepatic: Increased serum bilirubin (9%) Hypersensitivity: Hypersensitivity reaction (1%), infusion-related reaction (4%) Immunologic: Antibody development (6%) Infection: Neutropenic sepsis (1%) Nervous system: Malaise (7%), paresthesia (10%) Neuromuscular & skeletal: Back pain (10%), limb pain (6%), muscle spasm (6%), musculoskeletal pain (6%), ostealgia (7%) Ophthalmic: Dry eye syndrome (5%), increased lacrimation (5%) Respiratory: Dyspnea (10%), flu-like symptoms (5%), nasopharyngitis (9%), rhinorrhea (7%) Frequency not defined: Cardiovascular: Cardiac arrhythmia, cardiomyopathy, hypertension, left ventricular dysfunction Respiratory: Pneumonitis, pulmonary fibrosis, pulmonary toxicity |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/pertuzumab-and-trastuzumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

